| Literature DB >> 33133689 |
Fansu Meng1, Anwarul Hasan2,3, Mohammad Mahdi Nejadi Babadaei4, Pegah Hashemi Kani5, Amir Jouya Talaei5, Majid Sharifi6, Tiange Cai7, Mojtaba Falahati6, Yu Cai8,9,10.
Abstract
BACKGROUND: Microscopic patches as quite promising platforms in transdermal drug delivery suffer from conventional injections. In other hand, a wide range of pharmacokinetics, ranging from fast oral administration to sustained drug delivery, can be implemented with the help of microneedle arrays (MNAs). AIM OF REVIEW: Hence, in this paper, we overviewed different kinds of MNAs such as solid/coated, hollow, porous, hydrogel/swellable, and merged-tip geometry followed by introducing different types of material (silicon, glass, ceramics, dissolving and biodegradable polymers, and hydrogel) used for fabrication of MNAs. Afterwards, some conventional and brand-new simple and customizable MN mold fabrication techniques were surveyed. Polymeric MNAs have received a great deal of attention due to their potential biocompatibility and biodegradability in comparison to other materials. Therefore, we also covered different kinds of polymers such as hydrogel/swellable, dissolving and biodegradable analogues used for the development of MNAs as potential candidates in drug delivery systems (DDSs). Finally, we discussed different challenges and future perspectives in the aspect of MNAs-based drug delivery platforms. KEY SCIENTIFIC CONCEPTS OF REVIEW: This review may provide guidelines for the rational design of polymeric MNAs-based DDSs for promising programmable drug release and enhanced therapeutic effect.Entities:
Keywords: Biodegradable polymers; Dissolving polymers; Drug delivery; Fabrication method; Hydrogel polymers; Microneedle array
Year: 2020 PMID: 33133689 PMCID: PMC7584683 DOI: 10.1016/j.jare.2020.07.017
Source DB: PubMed Journal: J Adv Res ISSN: 2090-1224 Impact factor: 10.479
Different types of MNAs along with their advantages and disadvantages.
| Type of MNAs | Properties | Advantageous | Disadvantageous | Ref (s) |
|---|---|---|---|---|
| Solid/coated | Contain no drugs, or drug can be absorbed on its surface, synthesized by metals | Increase the permeability of drugs | Needs two step application, broken needles result in irritation, the high cost of fabrication method, non-biodegradability of metals | |
| Hollow | Can be loaded with drugs, fabricated by self-assembly and molding of soft materials | Higher stiffness, hydrophilic behavior and resistance can be achieved by using proper materials | Needs precise and expensive manufacturing technology, strong leakage or uncontrolled drug release, blocking the narrow channels | |
| Porous | Large variety of pore sizes can be achieved for drug loading, porosity and pore size can be controlled during synthesis | High drug loading capability, functionalization with different moieties, simple fabrication methods | Low strength and penetration ability, pore blockage, drug release | |
| Hydrogel/ swellable | Minimally-invasive devices used for controlled drug release | Significant biocompatibility, degradability, safe, simple, cheap, controlled drug release | Low mechanical strength, not suitable for very wet wounds | |
| Merged-tip MN | Uses elasto-capillarity-driven self-assembly for construction a micro merged-tip system | Can be tunable, simultaneous drug loading and volume control, no need for micromolding, controllable cavity volumes and fracture approaches, flexibility and fabrication simplicity | – |
Different types of material used for fabrication of MNAs along with their application.
| Material | Application | Ref (s) |
|---|---|---|
| Silicon | 1. Electroporation2. Transdermal drug delivery3. Deep brain drug infusion | |
| Glass | 1. Recordings of force2. Microinjection3. Facial atrophic acne scar | |
| Ceramics | 1. Transport interface2. Controlled release of a model vaccine3. Transdermal drug delivery | |
| Dissolving and biodegradable polymers | 1. Influenza vaccination2. Transdermal drug delivery3. Transdermal delivery of insulin4. Transdermal iron replenishment therapy5. Transdermal delivery of neurotoxin6. Patch and cream | |
| Swellable hydrogel polymers/ proteins | 1. Transdermal drug delivery2. Intradermal vaccination3. Regenerative internal/external surgical closure4. Glucose-responsive insulin delivery5. Sensing of specific circulating nucleic acids |
Different methods for fabrication of MNAs along with advantages and disadvantages of each method.
| Methods | Description | Advantageous | Disadvantageous | Ref(s) |
|---|---|---|---|---|
| Micromilling | Uses cutting tools to fabricate microscale arrays | Cost effective start-up, high resolution, and versatility about characteristic geometries and material choices | Require burrs removal, damage to the micro-tools, poor surface quality | |
| Direct laser micromachining | Molding of materials into desired morphology and dimension by laser | Simple, quick, precise method to handle, no contaminations, delicate designs on different metals, | High power consumption, burning or of the metal, side effects against human, not applicable for thick metals | |
| Chemical wet etching | Chemical process for removing the surface layers | Simple equipment, high rate, high selectivity | Needs large amounts of chemicals | |
| Electrical discharge machining | A device like MNA is fabricated by applying electrical discharges | Fabrication of complex shapes, high tolerance, Material hardness is not a concern, no distortion, well suited for delicate or fragile parts | Requires conductive materials, cost effective | |
| Drawing lithography | A strategy (thermal, magnetorheological, UV, air blowing) for the construction of a MNAs directly from 2D planar polymers | Fabrication of ultrahigh-aspect ratio (UHAR), stepwise controlling, fabrication of hybrid electro-MN | Long drawing time, expensive, not applicable in producing complex shapes | |
| UV-lithography | A fabrication strategy based on the pattern parts of a thin film of an agent | Cost effective, production of smaller feature size | Increased cost for new technology, complexity, concern about the reliability | |
| Deep reactive-ion etching | Plasma process for production of microstructure of silicon | Modifications can be made, creates a protective layer on the surface, creation of high sidewall angles | Requires suitable etch gasses, contamination of etch processes, requirement for dedicated machines | |
| Projection-based direct light processing | A layer-by-layer strategy for fabrication of MNAs | Simple and rapid fabrication of 3D structures | Not high-quality MNAs, not convenient for large scale-up production | |
| Fused filament fabrication (FFF) or fused deposition modeling (FDM) | Joint a filament of a material with the same material by heat or etc. | Uses low cost materials, fabricate more complex shaped MNAs | Resolution limitations, two-step process | |
| Scanning-based SLA | Laser beam tracks and draws each layer into resin layer | Simple and rapid fabrication of 3D structures | Not high-quality MNAs, not convenient for large scale-up production |
Fig. 1A: Fabrication of MNA mold. (a) CO2 laser cutter. (b) The acrylic mold was utilized to fabricate polydimethylsiloxane (PDMS) MNA mold [22]. B: Polymer casting and MNA fabrication approach. (a) Treating PDMS mold in oxygen. (b) Submerging the mold in polyvinyl alcohol (PVA) solution with phenol red dye. (c) Condensation of solution. (d) Dehydration of the mold. (e) Pilling off the MN patch. (f) Fabricated PVA MN patch (g) [22]. C: MNAs fabrication based on 3D printing. (a) MNA basin design by a Form 2 SLA printer. (b) MNA master mold construction approach (i) the 3D printed MNA basin; (ii) washing, UV curing and baking; (iii) filing with UV-curable resin; (iv) UV curing and baking; (v) MNA master; (vi) silicone casting; (vii) degassed process; (viii) demolding [21]. Reprined with permission from Refs [21], [22]. Copyright (2018) and (2019), Nature Publishing Group.
Fig. 2A: Different kinds of hydrogels and delivery routes per each [31]. (B) Fabrication of hydrogel microparticles (HMPs) through (a) Batch emulsions. (b) Microfluidic emulsions. (c) Lithography. (d) Electrohydrodynamic spraying. (e) Mechanical fragmentation methods [34]. Reprined with permission from Refs [31], [34]. Copyright (2016) and (2019), Nature Publishing Group.
Fig. 3A: (a) and (b) Microlancer. (c) The positioning of the hole. (d) Activation of the system. (e) Drug release and desolvation. B:(a) Plasma glucose level in diabetic mice over time. (b) Plasma insulin concentrations over time. (c) Insulin labeled FITC signal comparison of Microlancer and (d) patch [35]. C: Schematic illustration of simultaneous application of DMNA and serum. D: Distribution images of Alexa Fluor 568 dye (white arrow and dots) in serum and Alexa Fluor 488 dye (white arrow) loaded into DMNA patches (black arrow and dots) [36]. E: (a) Microscopic images of DMNAs. (b) Rhodamine delivery inside skin. (c) FITC delivery. F: Protein expression of β-catenin, PCNA, loricrin, and K14 [37]. Reprined with permission from Refs [35], [36], [37]. Copyright (2015), Nature Publishing Group; Copyright (2017), ACS; Copyright (2018), Elsevier.
Drug-loaded DMNAs and their potential use in treatment of skin disorders.
| Drug | Application | Ref(s) |
|---|---|---|
| Protein Delivery | Treatment of skin disorders | |
| Human growth hormone | Wound healing | |
| Soluble and particulate antigens | Vaccine/Treatment of skin disorders | |
| Fibroblast growth factor | Local therapy of skin wounds | |
| Green tea extracts | Antibacterial | |
| Cosmeceutical relevant peptides | Treatment of skin disorders | |
| Methylene blue | Photodynamic antimicrobial chemotherapy of infected wounds | |
| Transdermal delivery of collagen I | Treatment of skin disorders | |
| Cell delivery | Wound healing | |
| Adenosine | Improve skin wrinkles, dermal density, elasticity and hydration | |
| STAT3 siRNA | Melanoma | |
| ROS‐responsive MN | Acne Vulgaris | |
| Cosmeceuticals relevant nucleoside and peptides | Improvement of wrinkles | |
| Bleomycin | Inhibiting hypertrophic scar | |
| Triamcinolone | Treatment of keloids | |
| Methotrexate | Treatment of psoriasis |
Fig. 4A: (a) Variations in clinical morphology of skin. (b) Score of AD (SCORAD). (c) Trans-epidermal water loss (TEWL). (d) H&E-staining of skin. (e) Epidermal thickness. (f) Whole cell count. (g) Eosinophil count [41]. B: (a) Fluorescence microscopic images captured from skin 1 and 24 h after the administration of MNAs transferring FITC-labeled peptide. (b) Tumor growth [42]. Reprined with permission from Refs [41], [42]. Copyright (2018), Elsevier; Copyright (2019), ACS.